Literature DB >> 7371699

Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients.

T L Svendsen, S Rasmussen, O J Hartling, P E Nielsen, J Trap-Jensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7371699     DOI： 10.1007/bf00561670

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  21 in total

1.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

2.  EFFECT OF REPEATED EXERCISE ON THE LESSER CIRCULATION.

Authors:  J WIDIMSKY; E BERGLUND; R MALMBERG
Journal:  J Appl Physiol       Date:  1963-09       Impact factor: 3.531

3.  The clinical results of oral and parenteral administration of 2-(N'p-tolyl-N'-m-hydroxyphenylaminomethyl) imidazoline hydrochloride (regitine) in the treatment of hypertension and an evaluation of the cerebral hemodynamic effects.

Authors:  J H MOYER; C CAPLOVITZ
Journal:  Am Heart J       Date:  1953-04       Impact factor: 4.749

4.  Control of the splanchnic circulation in man. Role of beta-adrenergic receptors.

Authors:  H L Price; L H Cooperman; J C Warden
Journal:  Circ Res       Date:  1967-09       Impact factor: 17.367

5.  Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension.

Authors:  P Lund-Johansen; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

6.  Labetalol in long-term treatment of hypertension.

Authors:  B N Prichard; A J Boakes
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

7.  Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension.

Authors:  M H Frick; P Pörsti
Journal:  Br Med J       Date:  1976-05-01

8.  Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension.

Authors:  B N Prichard; F O Thompson; A J Boakes; A M Joekes
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06

9.  Haemodynamic effects of long-term oral labetalol.

Authors:  R C Edwards; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

10.  Acute hemodynamic effects of an alpha- and beta-receptor blocking agent (AH 5158) on the systemic and pulmonary circulation at rest and during exercise in hypertensive patients.

Authors:  G Koch
Journal:  Am Heart J       Date:  1977-05       Impact factor: 4.749
View more
  6 in total

Review 1.  Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.

Authors:  P Lund-Johansen; P Omvik
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

2.  Response of the systemic pulmonary circulation to labetalol at rest and during exercise.

Authors:  R Fagard; P Lijnen; A Amery
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 3.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

4.  Renal haemodynamics after chronic treatment with labetalol and propranolol.

Authors:  P L Malini; E Strocchi; S Negroni; E Ambrosioni; B Magnani
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 5.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

6.  Comparison of the effects of propranolol and labetalol on renal haemodynamics at rest and during exercise in essential hypertension.

Authors:  J S Larsen; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1980-08       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.